In ALSP, it might be expected that providing healthy myeloid donor cells, with normal CSF1R signaling, via HSCT during an early stage of disease could provide beneficial effects, possibly by boosting the microglia pool. This evidence concerns the gene CSF1R and Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.